Seagen Reports Results from Part C of P-II Trial (SGN35-027) for Adcetris (brentuximab vedotin) to Treat Early-Stage Classical Hodgkin Lymphoma
Shots:
- The updated efficacy & safety results from Part C of a P-II trial (SGN35-027) evaluating Adcetris + nivolumab, doxorubicin & dacarbazine (AN+AD). The therapy was jointly developed by Seagen & Takeda
- The results showed ORR (98%), CR rate (93%), TRAEs of any grade (≥30%), peripheral sensory neuropathy was primarily low grade (3% grade ≥3), immune-mediated AEs were consistent with the individual safety profile of nivolumab
- No cases of febrile neutropenia were reported with no grade 5 AEs, PFS results are not yet available & the results will be presented at the 17th ICML 2023. Adcetris received marketing authorization in 70+ countries for r/r HL and systemic ALCL
Ref: Businesswire | Image: Seagen
Related News:- Seagen’s Adcetris (brentuximab vedotin) Receives the US FDA’s Approval for High-Risk Hodgkin Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
